The remission rate was relatively higher in patients with R/R AML combined with FLT3-ITD mutation by applying the DAC+CLAG regimen(OR=10.84, 95%CI 1.48–288.50, P=0.04). Here, FLT3 is linked to acute myeloid leukemia.